# Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.

> **NCT06810726** · PHASE2 · RECRUITING · sponsor: **Estar Medical dba Medical Technologies, LTD** · enrollment: 30 (estimated)

## Conditions studied

- Diabetic Foot Ulcer
- Type 1 Diabetes Mellitus
- Type 2 Diabetes Mellitus (T2DM)
- Neuroischemic Foot Ulcer
- Chronic Wound of the Lower Limb (Leg Ulcer or Foot Ulcer)
- Chronic Wound Care

## Interventions

- **DEVICE:** Platelet Rich Plasma

## Key facts

- **NCT ID:** NCT06810726
- **Lead sponsor:** Estar Medical dba Medical Technologies, LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-15
- **Primary completion:** 2026-05-15
- **Final completion:** 2026-08-15
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-06-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06810726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06810726, "Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06810726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*